Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EIS-10700
- Development stage
- Unknown
- Lead developer
- Eisbach Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EIS-10700 is a novel, small-molecule allosteric inhibitor targeting the RNA helicase of SARS-CoV-2. Developed by Eisbach Bio using its proprietary ALLOS drug discovery engine, the compound is designed to suppress viral replication by targeting a molecular machine conserved across all known COVID-19 variants, potentially providing resistance to future mutations. The drug completed a Phase I clinical trial in May 2024, which evaluated its safety, tolerability, and pharmacokinetics in healthy volunteers under both fasted and fed conditions. The development was supported by the German Federal Ministry of Research (BMBF) as part of the EisCor2 project.
02
Targets
NSP13 (SARS-CoV-2 helicase)
Beyond the preview
Go deeper on EIS-10700.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EIS-10700.